Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2025-06-24 00:00:00 ET · period of report 2025-06-20 · accession 0001104659-25-062168 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-06-24 | 2025-06-20 | NVCT | Mosseri Marlio Charles | 10% | P - Purchase | $7.99 | +5,603 | 2.98M | +0.2% | +$44.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-20 | P | A | 5,603 | $7.99 | 2,981,806 | I By Emerald Hill Ventures SARL SPF. | — | — | (F1) Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. |